In a study from Rensselaer Polytechnic Institute, scientists have discovered a potential topical therapy to treat monkeypox.
The research stems from years of study spent on investigating the structures of viruses such as Zika, Dengue, herpes, coronaviruses, and hepatitis.
The past research and expertise in the interaction of virus proteins and polysaccharides, including existing drugs, aided researchers in the rapid discovery of a potential therapeutic.
The work is in its early stages, but the researchers believe that because the drugs used in the work are FDA-approved, there would be a rapid pathway for clinical testing and potential approval as a monkeypox therapy.
In the past three years, viral diseases have taken on a new urgency and focus in research and development with COVID-19 raising the profile of the power and complexities of viruses.
For years, researchers have looked at the structure of viruses and the interaction of different virus proteins with their human cellular targets.
This experience led the researchers to the discovery of this potential topical treatment.
This discovery shows the institute’s role as one of the top research universities in the world and the value and power of basic research at the interface of science and engineering in identifying solutions that impact society.
If you care about the pandemic, please read studies about how to protect against the rare monkeypox threat, and this face mask can capture and deactivate the COVID-19 virus.
For more information about the pandemic, please see recent studies about whether monkeypox is the next COVID-19, and results showing scientists find a universal antibody therapy to fight all COVID-19 variants.
The study was conducted by Fuming Zhang et al and published in Molecules.
Copyright © 2022 Knowridge Science Report. All rights reserved.